Multiomics strategy-based obesity biomarkers discovery for precision medicine
October 13, 2025 / obesity biomarkers / multiomics strategy / precision medicine / metabolic disorders / gut microbiome
Multiomics approaches reveal complex obesity biomarkers across genetic, metabolic, and microbial layers, offering insights for precision medicine, though clinical validation and integration remain limited, highlighting the need for longitudinal, population-specific studies.
Skipping breakfast raises metabolic syndrome risk
October 13, 2025 / metabolic syndrome / breakfast skipping / abdominal obesity / cardiometabolic risk / lifestyle intervention
Skipping breakfast is associated with increased risk of metabolic syndrome and its components—abdominal obesity, hyperglycemia, hypertension, and hyperlipidemia—highlighting breakfast as a potential low-cost intervention for cardiometabolic disease prevention, though evidence remains observational and heterogeneous.
Study Finds Sex-Based Differences in Metabolic Effects of HspB1 Overexpression in Obesity
October 13, 2025 / HspB1 overexpression / sex-based metabolism / obesity treatment / heat shock proteins / personalized medicine
Overexpression of heat shock protein B1 (HspB1) influences obesity-related metabolic responses differently in males and females, highlighting sex-specific genetic impacts and supporting the need for personalized obesity treatment strategies.
Tirzepatide and Semaglutide Most Efficacious for Weight Loss and Complication Remission in Obesity
October 7, 2025 / tirzepatide efficacy / semaglutide weight loss / obesity medications / cardiometabolic outcomes / diabetes remission
Tirzepatide and semaglutide are the most effective obesity medications for significant weight loss and remission of related complications, including type 2 diabetes and cardiovascular disease, according to a large network meta-analysis of over 60,000 patients.
Divergent Selection Alters Metabolism and Body Temperature in Obese Mice
October 11, 2024 / basal metabolic rate / thermoregulation obesity / energy expenditure / metabolic dysfunction / obesity risk
Low basal metabolic rate and unstable body temperature increase obesity risk in mice, highlighting the role of thermoregulatory lability in metabolic dysfunction and offering new insights into energy balance and obesity susceptibility.
Scientists found a smarter Mediterranean diet that cuts diabetes risk by 31%
October 12, 2025 / Mediterranean diet / type 2 diabetes prevention / calorie reduction / lifestyle intervention / PREDIMED-Plus study
A calorie-reduced Mediterranean diet combined with moderate exercise and professional support reduced type 2 diabetes risk by 31% in overweight adults, offering a sustainable, evidence-based strategy for diabetes prevention, per the large-scale PREDIMED-Plus trial in Spain.
Study Identifies Precision Biomarkers for Obesity Through Advanced Multiomics Techniques
October 13, 2025 / obesity biomarkers / multiomics analysis / metabolic disorder / targeted therapy / precision medicine
Advanced multiomics analysis has identified precision biomarkers for obesity, revealing its complex genetic and metabolic underpinnings and enabling development of more accurate diagnostics and targeted therapies for obesity-related complications.
Scientists discover brain cell “switch” that could reverse the effects of obesity
October 10, 2025 / astrocytes obesity / brain metabolism / cognitive impairment / obesity treatment / neural regulation
French researchers discovered that targeting astrocytes in the brain’s striatum can reverse obesity-related metabolic and cognitive impairments in mice, suggesting a novel therapeutic pathway that addresses both brain function and metabolism.
Air Pollution Can Contribute to Obesity and Diabetes
October 9, 2025 / air pollution / brown fat metabolism / insulin resistance / epigenetic regulation / metabolic disease
Chronic exposure to fine air pollution disrupts brown fat function through epigenetic changes, promoting insulin resistance and metabolic dysfunction, thereby linking environmental pollution to obesity and diabetes risk.
GLP-1s on the Rise: Cardiometabolic Targets Meet Dermatologic Possibilities
October 11, 2024 / GLP-1 therapy / inflammatory skin disease / cardiometabolic health / psoriasis treatment / obesity management
GLP-1 receptor agonists show emerging potential beyond diabetes, offering anti-inflammatory and weight-reduction benefits in psoriasis, hidradenitis suppurativa, and cardiometabolic disease, with early data supporting their integration into dermatologic care for obese or metabolically at-risk patients.
More Patients Using GLP-1 Drugs Prior To Weight-Loss Surgery
October 8, 2025 / GLP-1 drugs / bariatric surgery prep / obesity treatment / semaglutide tirzepatide / weight-loss medications
GLP-1 drug use before bariatric surgery rose 16-fold from 2020 to 2024, reflecting a major shift toward combined pharmacologic and surgical obesity management, especially among patients with and without type 2 diabetes.
Ultrasound-Activated Nanovesicles Transform Metabolic Processes
October 12, 2025 / ultrasound nanovesicles / metabolic reprogramming / targeted drug delivery / regenerative medicine / obesity treatment
Ultrasound-activated nanovesicles enable precise metabolic reprogramming, enhancing drug delivery and cellular repair. This novel approach shows promise for treating metabolic disorders like obesity and diabetes, with potential applications in regenerative medicine and personalized therapies.
New study links weight loss drugs to better liver health outcomes
October 10, 2025 / MASLD treatment / weight loss drugs / liver health / MASH therapy / metabolic liver disease
Anti-obesity medications show promise in improving liver health for patients with MASLD and MASH, potentially reducing liver fat, inflammation, and fibrosis—marking a shift toward pharmacologic support in managing metabolic liver disease.
Consumption of ‘polished rice’ directly linked to obesity, says surgeon
October 11, 2025 / polished rice obesity / metabolic syndrome / bariatric surgery / type 2 diabetes risk / southern India diet
High consumption of polished rice in southern India is linked to rising obesity and metabolic syndrome, increasing risks for type 2 diabetes and cardiovascular disease. Experts recommend dietary diversification and, in severe cases, bariatric surgery as effective intervention.
Novo Nordisk to acquire Akero Therapeutics for $5.2 billion
October 12, 2025 / Novo Nordisk acquisition / efruxifermin MASH / metabolic liver disease / FGF21 analogue / liver fibrosis treatment
Novo Nordisk will acquire Akero Therapeutics for $5.2B to advance efruxifermin (EFX), a promising FGF21 analogue in phase 3 trials for MASH. The deal expands Novo’s leadership in metabolic disease therapies, particularly liver fibrosis and cirrhosis.
Noninvasive Tests May Track Semaglutide Response in MASH
October 9, 2025 / semaglutide MASH response / noninvasive liver tests / fibrosis monitoring / NIT biomarkers / liver disease treatment
Noninvasive tests (NITs) effectively tracked semaglutide response in MASH patients, correlating with histologic improvement and reduced fibrosis progression, offering a potential alternative to liver biopsy for monitoring therapeutic outcomes.
Federal HIV Guidelines Add Chapter on Cardiovascular and Metabolic Health
October 8, 2025 / HIV guidelines update / cardiovascular risk HIV / GLP-1 therapy HIV / metabolic health HIV / statin use HIV
New federal HIV guidelines add a chapter on cardiovascular and metabolic health, emphasizing statin use, lifestyle interventions, and comorbidity management, while exploring GLP-1 therapies for weight and inflammation in HIV-positive individuals with emerging evidence.
Air pollution plays a significant role in the development of metabolic disorders
October 9, 2025 / air pollution metabolism / brown fat dysfunction / insulin resistance PM2.5 / epigenetic metabolic disease / HDAC9 KDM2B targets
Chronic exposure to fine air pollution (PM2.5) impairs brown fat function via epigenetic changes, driving insulin resistance and metabolic dysfunction. Key enzymes HDAC9 and KDM2B emerged as potential therapeutic targets for pollution-induced metabolic disease.
Metabolic regulation for the treatment of ischemic heart disease with stem cells and extracellular vesicles
October 10, 2025 / ischemic heart disease / stem cell therapy / cardiac metabolism / extracellular vesicles / myocardial repair
Stem cells and extracellular vesicles show promise in treating ischemic heart disease by restoring metabolic balance, enhancing myocardial repair, and addressing metabolic dysregulation that contributes to heart failure progression.